Contineum Therapeutics Prices Its IPO at $16 per Share
Friday, 5 April 2024, 06:18
Contineum Therapeutics IPO Pricing
Contineum Therapeutics, a clinical stage biopharmaceutical company, has set the price of its initial public offering at $16 per share. The company aims to raise gross proceeds of $110 million through this offering. This pricing is indicative of the investor confidence in the company's potential growth and market outlook.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.